FastWave Medical Extends Intellectual Property Portfolio with the Issuance of its Utility Patent for Novel Laser-IVL Technology
Summary
Millions of people worldwide have occlusive arterial disease that is further complicated by the presence of calcium, leading to increased morbidity and mortality. Through its advanced lithotripsy technology, FastWave aims to solve the gaps with current IVL solutions while improving ease of use and patient safety by reducing procedural complications. "Our growing IP portfolio is a key asset and catalyst to advance IVL technology with novel energy sources and design elements that can expand its use for more patients. FastWave Medical is at the forefront of developing intravascular lithotripsy (IVL) systems for calcific artery disease. With an emphasis on empowering physicians with procedural efficiency, FastWave aspires to redefine the sector by introducing next-generation IVL technologies that elevate the clinician experience and overall patient care.